CR10384A - Formulaciones de emulsion estable - Google Patents

Formulaciones de emulsion estable

Info

Publication number
CR10384A
CR10384A CR10384A CR10384A CR10384A CR 10384 A CR10384 A CR 10384A CR 10384 A CR10384 A CR 10384A CR 10384 A CR10384 A CR 10384A CR 10384 A CR10384 A CR 10384A
Authority
CR
Costa Rica
Prior art keywords
stable emulsion
emulsion formulations
calcimimetics
phlebitis
irritants
Prior art date
Application number
CR10384A
Other languages
English (en)
Inventor
Anuradha Gore
Anne Navratil
Seshadri Neervannan
Christopher W Spancake
Roger Zanon
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR10384A publication Critical patent/CR10384A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a formulaciones inyectables de agentes irritantes, tales como calcimimeticos, que son farmaceuticamente estables y demuestran una incidencia reducida de irritacion, dolor, flebitis, precipitacion y hemolisis despues que se inyectan.
CR10384A 2006-04-20 2008-10-21 Formulaciones de emulsion estable CR10384A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79382506P 2006-04-20 2006-04-20

Publications (1)

Publication Number Publication Date
CR10384A true CR10384A (es) 2008-11-11

Family

ID=38537687

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10384A CR10384A (es) 2006-04-20 2008-10-21 Formulaciones de emulsion estable

Country Status (14)

Country Link
US (1) US8779004B2 (es)
EP (1) EP2010150A2 (es)
JP (1) JP5199239B2 (es)
KR (1) KR20080110681A (es)
CN (1) CN101437490A (es)
AU (1) AU2007240317B2 (es)
BR (1) BRPI0710814A2 (es)
CA (1) CA2648939C (es)
CR (1) CR10384A (es)
EA (1) EA200802166A1 (es)
MX (1) MX2008013339A (es)
NO (1) NO20084368L (es)
WO (1) WO2007124465A2 (es)
ZA (1) ZA200808773B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1746976T3 (pl) 2004-05-03 2017-09-29 Merrimack Pharmaceuticals, Inc. Liposomy przydatne w systemie podawania leków
CA2657028A1 (en) * 2006-07-10 2008-01-17 Indiana University Research And Technology Corporation Methods for treating cystic kidney diseases
EP2114390A2 (en) * 2006-12-15 2009-11-11 Ruprecht-Karls-Universität Heidelberg Methods for treating podocyte-related disorders
AU2008233088B2 (en) * 2007-03-30 2013-09-26 Amgen Inc. Calcimimetic compounds for use in the treatment of bowel disorders
AU2009228069B9 (en) * 2008-03-28 2014-07-10 Amgen Inc. Calcimimetic compound for use in the treatment of epithelial injury
JP5468221B2 (ja) * 2008-08-04 2014-04-09 株式会社 メドレックス 難溶性薬物の静注用分散製剤
WO2010042642A1 (en) * 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
WO2011146583A2 (en) * 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
WO2012039768A2 (en) * 2010-09-24 2012-03-29 Texas Southern University Itraconazole formulations
US8658676B2 (en) * 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
US20120213855A1 (en) * 2011-02-17 2012-08-23 Cima Labs Inc. Dosage forms for weakly ionizable compounds
US9623087B2 (en) 2011-11-30 2017-04-18 3M Innovative Properties Company Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
EP2858513B1 (en) * 2012-06-07 2016-11-23 Cargill, Incorporated Pumpable fat compositions, use in feed and method for reducing their viscosity.
CA2878895A1 (en) * 2012-07-13 2014-01-16 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
CN102895187B (zh) * 2012-09-13 2015-05-06 西安力邦制药有限公司 注射用本芴醇脂肪乳的制备及其在疟疾治疗中的应用
ES2767151T3 (es) * 2012-10-24 2020-06-16 Cargill Inc Composición de emulsionante que contiene fosfolípidos
KR101951933B1 (ko) * 2013-03-12 2019-02-25 주식회사 아리바이오 라이소포스파티딜콜린 또는 이의 유도체를 포함하는 지질나노물질 및 이의 제조방법
CN103142477B (zh) * 2013-04-08 2015-09-30 薛巍 一种缓释秋水仙碱的含纳米载体微乳制剂的制备方法
CN106714787A (zh) * 2014-09-25 2017-05-24 富士胶片株式会社 含丙泊酚的水包油型乳液组合物及其制造方法
IL255148B2 (en) 2015-04-29 2023-04-01 Radius Pharmaceuticals Inc 1901 rad for use in a method to inhibit a cancerous growth or induce tumor regression in a patient who is resistant to the drug and/or has cancer positive for an estrogen receptor alpha mutation
SG10201912568PA (en) 2015-10-16 2020-02-27 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
KR101744203B1 (ko) * 2016-01-12 2017-06-20 (주)노터스생명과학 포스파티딜콜린을 유효성분으로 포함하는 신장질환 예방 또는 치료용 약학 조성물
CN105769765A (zh) * 2016-03-22 2016-07-20 辅必成（上海）医药科技有限公司 己酸羟孕酮脂肪乳注射液
KR101898282B1 (ko) * 2016-05-24 2018-09-13 주식회사 고려비엔피 항생제의 서방형 수의학적 조성물 및 이의 제조방법
CN117417263A (zh) 2017-01-05 2024-01-19 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
CN109200024A (zh) * 2017-07-07 2019-01-15 江苏恒瑞医药股份有限公司 西那卡塞药物组合物及其医药用途
CN109953979A (zh) * 2017-12-25 2019-07-02 江苏恒瑞医药股份有限公司 西那卡塞药物组合物及其医药用途
CN112423844A (zh) 2018-07-04 2021-02-26 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
KR102158824B1 (ko) * 2018-09-27 2020-09-23 한국화학연구원 자가미세유화 약물전달시스템을 이용한 난용성 약물의 약학적 제제
AU2019370565A1 (en) * 2018-11-02 2021-06-24 Ampersand Biopharmaceuticals, Inc. Management of risk of cation overload and electrolyte imbalance with topically applied buffers
US11992483B2 (en) 2021-03-31 2024-05-28 Cali Biosciences Us, Llc Emulsions for local anesthetics

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR511940A (fr) 1916-12-08 1921-01-07 Rene Emile Trottier Dispositif pour la commande des appareils destinés au classement ou à la séparation des matières solides de tous genres
JPS60258110A (ja) * 1984-06-05 1985-12-20 Daigo Eiyou Kagaku Kk 静脈注射可能なプロゲステロン乳化注射液
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5688938A (en) 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
MX9204881A (es) 1991-08-23 1993-04-01 Nps Pharma Inc Composicion farmaceutica que comprende moleculas activas, receptoras de calcio.
US5763569A (en) 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
ES2218531T3 (es) * 1991-08-23 2004-11-16 Nps Pharmaceuticals, Inc. Arilalquilaminas activas sobre los receptores del calcio.
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5858684A (en) 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
KR100296899B1 (ko) 1993-02-23 2001-10-24 쉘비 칼베르그 모르스 칼슘수용체활성분자
US5962314A (en) 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
PT1203761E (pt) * 1994-10-21 2005-04-29 Nps Pharma Inc Compostos activos do receptor de calcio
EP1258471B1 (en) 1996-05-01 2007-01-24 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
AU731146C (en) 1996-05-01 2005-02-03 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
US6362231B1 (en) 1996-07-08 2002-03-26 Nps Pharmaceuticals, Inc. Calcium receptor active compounds
TW483881B (en) 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
NZ503513A (en) * 1997-09-18 2004-12-24 Skyepharma Inc Sustained-release liposomal anesthetic compositions
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
CN1221249C (zh) * 1998-08-19 2005-10-05 斯凯伊药品加拿大公司 普鲁泊福的可注射水分散体
US6172091B1 (en) 1998-10-14 2001-01-09 Ortho-Mcneil Pharmaceutical, Inc. 1,2-Disubstituted cyclopropanes
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
JP2003535884A (ja) * 2000-06-16 2003-12-02 スカイファーマ・カナダ・インコーポレーテッド プロポフォールの改善された注射可能な分散物
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US6916956B2 (en) 2000-08-11 2005-07-12 Japan Tobacco, Inc. Calcium receptor antagonist
FR2820136A1 (fr) 2001-01-26 2002-08-02 Aventis Pharma Sa Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US7176322B2 (en) * 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
CA2494700C (en) 2002-08-26 2011-06-28 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
US20050101576A1 (en) 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US20060134145A1 (en) * 2002-12-06 2006-06-22 Otsuka Pharmaceutical Factory, Inc. Propofol-containing fat emulsions
DE602004024668D1 (de) 2003-04-23 2010-01-28 Japan Tobacco Inc CaSR-ANTAGONIST
CN1225242C (zh) * 2003-05-21 2005-11-02 浙江天皇药业有限公司 一种抗肿瘤药物毛兰素脂肪乳剂及其制备方法
CA2527203C (en) 2003-05-28 2010-08-17 Japan Tobacco Inc. Casr antagonist
DE602004023509D1 (de) * 2003-07-23 2009-11-19 Theravance Inc Pharmazeutische zusammensetzungen eines kurzwirkenden sedativen hypnosemittels
AU2006227429A1 (en) 2005-03-17 2006-09-28 Amgen Inc. Methods of decreasing calcification
FR2885129B1 (fr) 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
EP1882684B1 (en) 2005-05-19 2014-12-10 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
AU2006285080B2 (en) 2005-09-02 2012-05-03 Amgen Inc. Methods of modulating intestinal fluid balance
EP2114390A2 (en) 2006-12-15 2009-11-11 Ruprecht-Karls-Universität Heidelberg Methods for treating podocyte-related disorders

Also Published As

Publication number Publication date
JP2009534425A (ja) 2009-09-24
US8779004B2 (en) 2014-07-15
ZA200808773B (en) 2009-07-29
EP2010150A2 (en) 2009-01-07
WO2007124465A2 (en) 2007-11-01
CA2648939A1 (en) 2007-11-01
MX2008013339A (es) 2009-01-26
CA2648939C (en) 2014-07-08
WO2007124465A3 (en) 2008-04-10
BRPI0710814A2 (pt) 2011-08-16
CN101437490A (zh) 2009-05-20
AU2007240317B2 (en) 2012-11-29
EA200802166A1 (ru) 2009-06-30
NO20084368L (no) 2008-11-17
JP5199239B2 (ja) 2013-05-15
KR20080110681A (ko) 2008-12-18
AU2007240317A1 (en) 2007-11-01
US20070249520A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
CR10384A (es) Formulaciones de emulsion estable
GT200800276A (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
DOP2016000298A (es) Pirazolopiridinas y pirazolopirimidinas
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
BR112012018345A2 (pt) "compostos de heteroarila, bem como composições e usos dos mesmos"
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
MX2011011514A (es) Formulaciones de canabidiol y metodos para utilizarlas.
BRPI0914682B8 (pt) compostos de heteroarila e composições compreendendo os referidos compostos
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
DK2148670T3 (da) Titrering af tapentadol
CR20110466A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
BRPI0918360A2 (pt) composto, composição farmacêutica e usos de um composto
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
EA201291050A1 (ru) Комбинация лекарств с протеинсвязывающими пролекарствами
BRPI0916069A2 (pt) "composto, usos de um composto, composição farmacêutica, composição cosmética e usos cosméticos de uma composição"
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
EA201170512A1 (ru) Композиция для перорального введения
NI201100227A (es) Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amlodipina, su preparación y su aplicación terapéutica.
CR11406A (es) Conjugados de neurturina novedosos para uso farmaceutico
PA8846401A1 (es) Sinergismo antibiótico
DOP2013000115A (es) Formulación de un complejo que comprende clorhidrato de lercanidipina y valsartán y método para la preparación de la misma
ATE552832T1 (de) Antidepressivum-propharmaka
GT200500386A (es) Composicion que comprende una epotilona y metodos para producir dicha composicion
BR112012028506A2 (pt) "composições que compreenden extratos de abrótano ( artemisia abrotanum) e um composto de amina"

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)